Indian Bulk Drugmakers Sue Govt Over Bulk Drug Price Control
India's Bulk Drug Manufacturing Association (BDMA) has filed writpetitions against the federal government and the National Pharmaceutical Pricing Authority (NPPA) for their "ad hoc and arbitrary" price control policies. The case before the Delhi High Court will come up for hearing on January 27.
The BDMA has accused the government of not adhering to its price control guidelines and has justified the exclusion of eight drugs from price control based on the government's own criteria.
The BDMA, which represents over 300 drug majors, has urged the court to declare the controversial Drug (Price Control) Order 1995 (DPCO) invalid and void, or alternatively, issue a writ of mandamus or order directing the government to include or exclude various drugs marketed in India as per para 22.7.2 of the new Drugs Policy 1994.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze